Again, the T cell profiles of the tumor-infiltrating immune cells were evaluated by the CD3 and CD8 staining experiment in xenograft tumor tissues, and we found that the number of tumor-infiltrating CD3+ and CD8+ T cells were elevated in two combination groups compared with monotherapy group with either agent (Figures 6D,E). The gene discussed is CD8A; the disease is neoplasm.